Laboratory of Adipose Tissue Biology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic.
Physiol Res. 2024 Aug 31;73(Suppl 1):S295-S320. doi: 10.33549/physiolres.935396. Epub 2024 Jul 17.
Metabolic dysfunction-associated steatotic liver disease (MASLD) occurs in subjects with obesity and metabolic syndrome. MASLD may progress from simple steatosis (i.e., hepatic steatosis) to steatohepatitis, characterized by inflammatory changes and liver cell damage, substantially increasing mortality. Lifestyle measures associated with weight loss and/or appropriate diet help reduce liver fat accumulation, thereby potentially limiting progression to steatohepatitis. As for diet, both total energy and macronutrient composition significantly influence the liver's fat content. For example, the type of dietary fatty acids can affect the metabolism of lipids and hence their tissue accumulation, with saturated fatty acids having a greater ability to promote fat storage in the liver than polyunsaturated ones. In particular, polyunsaturated fatty acids of n-3 series (omega-3), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have been intensively studied for their antisteatotic effects, both in preclinical animal models of obesity and hepatic steatosis and in overweight/obese patients. Their effects may depend not only on the dose and duration of administration of omega-3, or DHA/EPA ratio, but also on the lipid class used for their supplementation. This review summarizes the available evidence from recent comparative studies using omega-3 supplementation via different lipid classes. Albeit the evidence is mainly limited to preclinical studies, it suggests that phospholipids and possibly wax esters could provide greater efficacy against MASLD compared to traditional chemical forms of omega-3 supplementation (i.e., triacylglycerols, ethyl esters). This cannot be attributed solely to improved EPA and/or DHA bioavailability, but other mechanisms may be involved. Keywords: MASLD • Metabolic dysfunction-associated steatotic liver disease • NAFLD • Non-alcoholic fatty liver disease • n-3 polyunsaturated fatty acids.
代谢相关脂肪性肝病(MASLD)发生于肥胖和代谢综合征患者中。MASLD 可由单纯性脂肪变性(即肝脂肪变性)进展为脂肪性肝炎,其特征为炎症改变和肝细胞损伤,显著增加死亡率。与减重和/或适当饮食相关的生活方式措施有助于减少肝脏脂肪堆积,从而可能限制其向脂肪性肝炎的进展。至于饮食,总能量和宏量营养素组成均显著影响肝脏的脂肪含量。例如,膳食脂肪酸的类型可以影响脂质的代谢,从而影响其组织堆积,与多不饱和脂肪酸相比,饱和脂肪酸促进肝脏脂肪储存的能力更强。具体而言,n-3 系列多不饱和脂肪酸(ω-3),如二十二碳六烯酸(DHA)和二十碳五烯酸(EPA),因其具有抗脂肪变性作用而受到广泛研究,无论是在肥胖和肝脂肪变性的临床前动物模型中,还是在超重/肥胖患者中都是如此。其作用可能不仅取决于 ω-3、DHA/EPA 比值的剂量和持续时间,还取决于用于补充的脂质种类。本综述总结了使用不同脂质种类进行 ω-3 补充的近期比较研究的现有证据。尽管证据主要限于临床前研究,但它表明与传统的 ω-3 补充化学形式(即三酰甘油、乙酯)相比,磷脂和可能的蜡酯可能对 MASLD 具有更大的疗效。这不能仅仅归因于 EPA 和/或 DHA 生物利用度的提高,可能还涉及其他机制。关键词:MASLD • 代谢相关脂肪性肝病 • NAFLD • 非酒精性脂肪性肝病 • n-3 多不饱和脂肪酸